Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 5, 2015, Pages 490-496

  Song, Ivy ^a   Borland, Julie ^a   Arya, Niki ^a   Wynne, Brian ^a   Piscitelli, Stephen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

calcium carbonate; dolutegravir; drug interaction; ferrous fumarate; pharmacokinetics

Indexed keywords

CALCIUM CARBONATE; DOLUTEGRAVIR; FERROUS FUMARATE; FERROUS ION; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTACT DERMATITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOOD; HEADACHE; HUMAN; HUMAN EXPERIMENT; IRON THERAPY; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MINERAL SUPPLEMENTATION; NORMAL HUMAN; OPEN STUDY; PARAMETERS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; DIETARY SUPPLEMENT; DRUG ANTAGONISM; FOOD DRUG INTERACTION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CALCIUM CARBONATE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DRUG ANTAGONISM; FASTING; FEMALE; FERROUS COMPOUNDS; FOOD-DRUG INTERACTIONS; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE;

EID: 84926010867     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.439     Document Type: Article

References (14)

1. Song I, Chen S, Lou Y, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients. In: Posters of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa. 2009. Poster WEPEB250. International AIDS Society, Geneva, Switzerland.
2. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010; 54: 254-258.
3. Arribas J, Lazzarin A, Raffi F, et al. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276). In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract THLBB205. International AIDS Society, Geneva, Switzerland.
4. Underwood M, Johns B, Sato A, Fujiwara T, Spreen W,. S/GS K1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. In: Posters of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa. 2009. Poster WEPEA098. International AIDS Society, Geneva, Switzerland.
5. Castagna A, Maggiolo F, Penco G,. et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014; 210: 354-362.
6. Ramanathan S, Shen G, Hinkle J, et al. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents. In: Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary. 2007. Abstract 69. Virology Education, Utrecht, The Netherlands.
7. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010; 54: 4999-5003.
8. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011; 66: 1567-1572.
9. Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012; 56: 1627-1629.
10. Song I, Chen S, Piscitelli S, Min S,. Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naive subjects. In: Abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado. 2013. Abstract A-1573. American Society for Microbiology, Washington, DC.
11. Viread [package insert] Foster City, CA: Gilead Sciences, Inc; 2013.
12. Belperio PS, Rhew DC,. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004; 116 (suppl 7 A): 27S-43S.
13. Ferrous fumarate (Rx, OTC). Medscape http://reference.medscape.com/drug/feostat-sequels-ferrous-fumarate-342163.
14. Actonel [package insert] Rockaway, NJ: Warner Chilcott Company, LLC; 2013.